Article
A polymorphism in the type one complement receptor (CR1) involves an additional cysteine within the C3b/C4b binding domain that inhibits ligand binding.
Molecular immunology - 1 Jul 2007
Birmingham Daniel J, Irshaid Fawzi, Gavit Katherine F, Nagaraja Haikady N, Yu C Yung, Rovin Brad H, Hebert Lee A
Abstract excerpt
The type one complement receptor (CR1) contains a variable number of binding domains for C3b and C4b, formed through a nearly identical set of repeating units known as short consensus repeats (SCRs). Each SCR contains four cysteines that, by forming two disulfide bonds, impart a conformation critical for function. In this study, we identified a CR1 single nucleotide polymorphism (1597C>T) that results in an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.